Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy
Contributors
Ben Khelil, MyriamPublished in
Cancer immunology research, vol. 14, no. 1, p. 139-154Publication date
2026-01-08First online date
2025-10-20Abstract
Keywords
- Animals
- CD8-Positive T-Lymphocytes / immunology
- CD8-Positive T-Lymphocytes / metabolism
- Cell Line, Tumor
- Disease Models, Animal
- Female
- Histocompatibility Antigens Class I / immunology
- Humans
- Immunotherapy / methods
- Mice
- Neoplasms / immunology
- Neoplasms / therapy
- Receptors, Antigen, T-Cell / genetics
- Receptors, Antigen, T-Cell / immunology
- Receptors, Antigen, T-Cell / metabolism
- Transcription Factors / genetics
- Transcription Factors / immunology
- Transcription Factors / metabolism
- Xenograft Model Antitumor Assays
UNIGE research groups
Citation (ISO format)
BEN KHELIL, Myriam et al. Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy. In: Cancer immunology research, 2026, vol. 14, n° 1, p. 139–154. doi: 10.1158/2326-6066.CIR-24-0207
Main files (2)
Article (Published version)
Article (Accepted version)
Identifiers
- PID : unige:197249
- DOI : 10.1158/2326-6066.CIR-24-0207
- PMID : 41114529
